Chao-Kai Chou

Chao-Kai Chou

Auto-generated profile, based on publicly available information

Chao-Kai Chou

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SJShiping JIAO
Shiping JIAO
WXWeiya Xia
Weiya Xia
HYHirohito Yamaguchi
Hirohito Yamaguchi
YWYongkun Wei
Yongkun Wei
MCMei-Kuang Chen
Mei-Kuang Chen
MHMien-Chie Hung
Mien-Chie Hung
Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates PARP inhibitor (PARPi) in tumor suppression. Experimental Design: Breast cancer cell lines, xenograft tumors, and syngeneic tumors treated with PARPi were assessed for PD-L1 expression by immunoblotting, IHC, and FACS analyses. The phospho-kinase antibody array screen was used to explore the underlying mechanism of PARPi-induced PD-L1 upregulation. The therapeutic efficacy of PARPi alone, PD-L1 blockade alone, or their combination was tested in a syngeneic tumor model. The tumor-infiltrating lymphocytes and tumor cells isolated from syngeneic tumors were analyzed by CyTOF and FACS to evaluate the activity of antitumor immunity in the tumor microenvironment. Results: PARPi upregulated PD-L1 expression in breast cancer cell lines and animal models. Mechanistically, PARPi inactivated GSK3β, which in turn enhanced PARPi-mediated PD-L1 upregulation. PARPi attenuated anticancer immunity via upregulation of PD-L1, and blockade of PD-L1 resensitized PARPi-treated cancer cells to T-cell killing. The combination of PARPi and anti-PD-L1 therapy compared with each agent alone significantly increased the therapeutic efficacy in vivo. Conclusions: Our study demonstrates a cross-talk between PARPi and tumor-associated immunosuppression and provides evidence to support the combination of PARPi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer. Clin Cancer Res; 23(14); 3711–20. ©2017 AACR.

1 August 2007 in Cell
Verified
Journal Article
Closed access
Dung-Fang LeeDung-Fang Lee
Dung-Fang Lee
HKHsu-Ping Kuo
Hsu-Ping Kuo
CCChun-Te Chen
Chun-Te Chen
JHJung-Mao Hsu
Jung-Mao Hsu
CCChao-Kai Chou
Chao-Kai Chou
MHMien-Chie Hung
Mien-Chie Hung

1 February 2018 in Cancer Cell
Verified
Journal Article
Closed access
CLChia-Wei Li
Chia-Wei Li
SLSeung-Oe Lim
Seung-Oe Lim
ECEzra M. Chung
Ezra M. Chung
YKYong-Soo Kim
Yong-Soo Kim
APAndrew H. Park
Andrew H. Park
MHMien-Chie Hung
Mien-Chie Hung

1 July 1999 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HLHsiao-Sheng Liu
Hsiao-Sheng Liu
MJMING-SHIOU JAN
MING-SHIOU JAN
CCChao-Kai Chou
Chao-Kai Chou
PCPing-Hong Chen
Ping-Hong Chen
NKNir-Jihn Ke
Nir-Jihn Ke

1 August 2019 in Cancer Cell
Verified
Journal Article
Closed access
HLHeng-Huan Lee
Heng-Huan Lee
YWYing-Nai Wang
Ying-Nai Wang
WXWeiya Xia
Weiya Xia
CCChia-Hung Chen
Chia-Hung Chen
KRKun-Ming Rau
Kun-Ming Rau
MHMien-Chie Hung
Mien-Chie Hung

1 October 2009 in Molecular Cell
Verified
Journal Article
Closed access
Dung-Fang LeeDung-Fang Lee
Dung-Fang Lee
HKHsu-Ping Kuo
Hsu-Ping Kuo
MLMo Liu
Mo Liu
CCChao-Kai Chou
Chao-Kai Chou
WXWeiya Xia
Weiya Xia
MHMien-Chie Hung
Mien-Chie Hung